What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Disease
Tsutomu Takeuchi spends much of his time researching Internal medicine, Rheumatoid arthritis, Surgery, Gastroenterology and Immunology.
His study connects Placebo and Internal medicine.
His Rheumatoid arthritis study incorporates themes from Methotrexate, Arthritis, Clinical endpoint, Randomized controlled trial and Rheumatism.
The Surgery study combines topics in areas such as Severity of illness, Risk factor and Rheumatoid factor.
His Gastroenterology research also works with subjects such as
- Pneumocystis pneumonia which connect with Pneumonitis,
- Eye disease most often made with reference to Pathology.
His Immunology research focuses on Endocrinology and how it relates to Immunoglobulin G.
His most cited work include:
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (3425 citations)
- Innate production of T H 2 cytokines by adipose tissue-associated c-Kit + Sca-1 + lymphoid cells (1359 citations)
- Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force (730 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Rheumatoid arthritis, Immunology, Gastroenterology and Rheumatology.
Tsutomu Takeuchi has researched Internal medicine in several fields, including Placebo and Surgery.
The various areas that he examines in his Rheumatoid arthritis study include Methotrexate, Arthritis, Randomized controlled trial, Infliximab and Physical therapy.
The study incorporates disciplines such as Adalimumab, Discontinuation and Pharmacology in addition to Methotrexate.
His Rheumatology research is multidisciplinary, incorporating perspectives in Rheumatism and Etanercept.
Tsutomu Takeuchi combines subjects such as Molecular biology and Antigen with his study of Antibody.
He most often published in these fields:
- Internal medicine (45.39%)
- Rheumatoid arthritis (37.81%)
- Immunology (26.49%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (45.39%)
- Rheumatoid arthritis (37.81%)
- In patient (12.49%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Rheumatoid arthritis, In patient, Gastroenterology and Bristol-Myers are his primary areas of study.
Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Placebo.
His Rheumatoid arthritis research is multidisciplinary, relying on both Methotrexate, Discontinuation, Phases of clinical research, Arthritis and Adverse effect.
His Gastroenterology research integrates issues from Biomarker, Rheumatoid factor, Refractory and Glucocorticoid.
Tsutomu Takeuchi has included themes like Acr20 response, Disease characteristics, Signs and symptoms, Safety profile and Study drug in his Bristol-Myers study.
Tsutomu Takeuchi studied Disease and Immunology that intersect with Cytotoxic T cell.
Between 2018 and 2021, his most popular works were:
- Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment (100 citations)
- Translating IL-6 biology into effective treatments. (68 citations)
- Effect of Filgotinib vs Placebo on Clinical Response in Patients with Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial (65 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Disease
His scientific interests lie mostly in Internal medicine, Rheumatoid arthritis, Placebo, Rheumatology and Methotrexate.
His Internal medicine study frequently draws connections between adjacent fields such as Gastroenterology.
His studies deal with areas such as Adverse effect, Clinical trial, Discontinuation and Incidence as well as Rheumatoid arthritis.
His research investigates the connection between Placebo and topics such as Pulmonary embolism that intersect with issues in Mace.
His Rheumatology study integrates concerns from other disciplines, such as Overlap syndrome, Immunology, Giant cell arteritis, Vasculitis and CD14.
His studies in Methotrexate integrate themes in fields like Response rate, Adalimumab and Arthritis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
